Positive News SentimentPositive NewsNASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis $8.76 -0.23 (-2.56%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Exicure Stock (NASDAQ:XCUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exicure alerts:Sign Up Key Stats Today's Range$8.50▼$8.8350-Day Range$8.44▼$11.8652-Week Range$1.44▼$36.00Volume2,576 shsAverage Volume556,431 shsMarket Capitalization$55.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewExicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More… Exicure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreXCUR MarketRank™: Exicure scored higher than 36% of companies evaluated by MarketBeat, and ranked 797th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Exicure. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExicure has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exicure's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently decreased by 4.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted1.24% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently decreased by 4.60%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentExicure has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Exicure this week, compared to 1 article on an average week.Search Interest1 people have searched for XCUR on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exicure's insider trading history. Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address XCUR Stock News HeadlinesExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 13, 2025 | Brownstone Research (Ad)Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comSee More Headlines XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed this year? Exicure's stock was trading at $13.67 at the start of the year. Since then, XCUR stock has decreased by 35.3% and is now trading at $8.8450. View the best growth stocks for 2025 here. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) released its quarterly earnings data on Tuesday, March, 18th. The company reported ($3.39) EPS for the quarter. When did Exicure's stock split? Exicure's stock reverse split on Tuesday, August 27th 2024. The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exicure own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET). Company Calendar Last Earnings3/18/2025Today6/13/2025Next Earnings (Estimated)6/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XCUR CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.91 million Net MarginsN/A Pretax Margin-799.80% Return on Equity-190.90% Return on Assets-36.75% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$500 thousand Price / Sales111.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.05Miscellaneous Outstanding Shares6,318,000Free Float2,504,000Market Cap$55.88 million OptionableNot Optionable Beta3.71 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:XCUR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.